Tomorrow's Cell
Therapies, Today®
Pluristyx provides induced pluripotent stem cells and the expertise to accelerate the development and commercialization of revolutionary cellular therapies.
We Simplify the Stem Cell Therapy
Development Process
We Simplify the Stem Cell Therapy
Development Process
Why Pluristyx, powered by panCELLa?
Pluristyx's innovative technologies along with the panCELLa Platform, provides clients with the necessary expertise and tools to support and accelerate the development and commercialization of cellular products.
Our iPSC platform offers our clients a single point of access to our research and clinical grade stem cells, proprietary gene edits and end-to-end support throughout the product development pathway.
End-to-End Solutions
With our enlarged portfolio of unique non-modified and genetically engineered iPSC-based products, Pluristyx can assist you at any stage in your product development workflow.
Gene Edits
Offering an array of gene editing technologies and our proprietary FailSafe® edit resulting in unparalleled functional control of commercial products.
Clinical Path iPSC
Leading provider of gene-edited iPSC and cell therapy solutions, accelerating the path to clinic and providing the best route to commercialization.
Scientific Expertise
Veteran expertise from industry leaders in the field of stem cell biology, developmental genetics and cell therapy.
End-to-End Solutions
With our enlarged portfolio of unique non-modified and genetically engineered iPSC-based products, Pluristyx can assist you at any stage in your product development workflow.
Gene Edits
Offering an array of gene editing technologies and our proprietary FailSafe® edit resulting in unparalleled functional control of commercial products.
Clinical Path iPSC
Leading provider of gene-edited iPSC and cell therapy solutions, accelerating the path to clinic and providing the best route to commercialization.
Scientific Expertise
Veteran expertise from industry leaders in the field of stem cell biology, developmental genetics and cell therapy.
Try Before You Buy
Would you like to experience our technology firsthand before committing to a license agreement? We welcome you to have access to our various product offerings before you purchase a commercial license.
Your Problems, Our Solution - panCELLa Platform
To overcome any obstacle you’re facing, panCELLa, a novel iPSC platform for rapid, efficacious, and high-quality iPS cell therapy development, can turn your bold ideas into reality.
Your Problems,
Our Solution -
panCELLa Platform
To overcome any obstacle you’re facing, panCELLa, a novel platform for rapid, efficacious, and high-quality iPSC therapy development, can turn your bold ideas into reality.
About Pluristyx
Pluristyx, powered by panCELLa offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.
About Pluristyx
Pluristyx powered by panCELLa offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.
About Pluristyx
Pluristyx powered by panCELLa offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.
Latest News
Pluristyx launches PluriFreeze™ Cryopreservation Media to Accelerate Stem Cell Therapy Development
Seattle, WA April 3, 2024 – Pluristyx, a leading provider of tools, technologies, and services for cellular therapies, is pleased to announce the release of its proprietary cryopreservation medium solution, PluriFreeze™. Immediately available in a Research Use Only (RUO) formulation...
BioCentriq Strengthens Partnership with Pluristyx to Accelerate the Development of iPSC-Derived NK Cell Therapies
Newark, New Jersey March 7, 2024 BioCentriq, Inc., a global cell therapy Contract Development and Manufacturing Organization (CDMO), is proud to announce a significant enhancement to its partnership with Pluristyx Inc., an early stage, privately held biotechnology company specializing in...
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development. WILMINGTON, Mass. – February 20, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered...